EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy

Tabea A Elsener iD, Jo-Anne R Dillon iD, William M Shafer iD, Christoph M Tang iD

Clinical Microbiology Reviews · 11.06.2026 · 39 (2)

DOI: 10.1128/cmr.00252-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 11.06.2026. Verfasst von Tabea A Elsener und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea, Anti-Bacterial Agents, Plasmids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAID NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gonococcal disease is a serious threat to reproductive health, with cases and antimicrobial resistance steadily increasing. Currently, the β-lactam antibiotic ceftriaxone is the mainstay of treatment, while doxycycline post-exposure prophylaxis (DoxyPEP) is being implemented to reduce bacterial sexually transmitted infections. Neisseria gonorrhoeae , the causative agent of gonorrhoea, can harbor two resistance plasmids, p bla and pConj, which confer resistance to penicillin and tetracycline/doxycycline, respectively. Additionally, over 90% of isolates carry a small plasmid, pCryp, whose function remains unclear. Of concern, p bla -encoded β-lactamases only differ from extended-spectrum β-lactamases by one or two amino acid changes. DoxyPEP is completely ineffective against isolates carrying pConj expressing tetM. tetM -mediated resistance has increased in the gonococcus following introduction of DoxyPEP and is widespread in low- and middle-income countries. Therefore, plasmids pose a significant risk to the successful management of gonococcal infection. Here, we review current knowledge of the epidemiology and biology of gonococcal plasmids. We describe the hierarchy of acquisition and dependencies between plasmids in N. gonorrhoeae and their subsequent evolution, transfer dynamics, fitness costs, and benefits to provide a better understanding of the implications of the plasmids on public health interventions for controlling and treating gonococcal infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeGonorrheaAnti-Bacterial AgentsPlasmidsHumansDrug Resistance, Bacterial

Stichwörter der Autor:innen

DoxyPEPNeisseria gonorrhoeaegonococcuspConjpblaplasmids

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
  • Department of Biochemistry, Microbiology and Immunology, College of Medicine and the Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Microbiology and Immunology, Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, Georgia, USA.

ORCID-Profile: Tabea A Elsener, Jo-Anne R Dillon, William M Shafer, Christoph M Tang

Förderung

  • BLRD VA
  • NIAID NIH HHS
  • Wellcome Trust
  • Jesus College, University of Oxford

Zitieren

APA

Elsener, T. A., Dillon, J. A. R., Shafer, W. M., & Tang, C. M. (2026). Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy. Clinical Microbiology Reviews, 39(2). https://doi.org/10.1128/cmr.00252-25

Vancouver

Elsener TA, Dillon JAR, Shafer WM, Tang CM. Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy. Clinical Microbiology Reviews. 2026;39(2). doi:10.1128/cmr.00252-25

BibTeX
@article{Elsener2026,
  author = {Elsener, Tabea A and Dillon, Jo-Anne R and Shafer, William M and Tang, Christoph M},
  title = {Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy},
  journal = {Clinical Microbiology Reviews},
  year = {2026},
  volume = {39},
  number = {2},
  doi = {10.1128/cmr.00252-25}
}
Kostenlos starten →